EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	14	"632008"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L2	2	("6518311").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/05 08:25
L3	358	(562/579).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/05 08:25
L4	924	(514/558).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/05 08:25
L5	296	(554/213).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/05 08:25
L6	110	propyloctanoic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L7	0	hydroxypropyloctanoic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L8	475875	hydroxy	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L9	22	L6 same L8	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L10	19	L6 near10 L8	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L11	2	"03007992"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25

EAST Search History

L12	5	"2003007992"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 08:25
L13	24889	"S100"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 09:21
L14	2	l6 and l13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 09:21
L15	35762	neurodegen$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 09:22
L16	430	l13 and l15	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 09:22
L17	0	l5 and l16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/09/05 09:22

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:43:27 ON 04 SEP 2007

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:43:41 ON 04 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2007 HIGHEST RN 945955-20-4
DICTIONARY FILE UPDATES: 3 SEP 2007 HIGHEST RN 945955-20-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> logoff hold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 2.70 2.91

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:46:59 ON 04 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 13:47:15 ON 04 SEP 2007
FILE 'REGISTRY' ENTERED AT 13:47:15 ON 04 SEP 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL

```
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      2.70       2.91

=> e 7-oxo-2-octylpropanoic acid/cn
E1            1     7-OXO-2-METHYL-3,5-DIPHENYL-4,7-DIHYDROPYRAZOLO(1,5-A)
                    PYRIMIDINE/CN
E2            1     7-OXO-2-OCTENOIC ACID ETHYL ESTER/CN
E3            0 --> 7-OXO-2-OCTYLPROPANOIC ACID/CN
E4            1     7-OXO-2-PHENYL-4,7-DIHYDROTHIENO(3,2-B)PYRIDINE-6-CARBONITRI
                    LE/CN
E5            1     7-OXO-2-PHENYLAMINO-7H-PYRIDO(2,3-D)PYRIMIDIN-8-YLACETIC ACI
                    D METHYL ESTER/CN
E6            1     7-OXO-20-EPIMINOVINCININE/CN
E7            1     7-OXO-24-S,25-EPOXYCHOLESTEROL/CN
E8            1     7-OXO-3-OXABICYCLO(3.3.0)OCTANE/CN
E9            1     7-OXO-3-PHENYLTHIAZOLO(4,5-D)PYRIMIDINE-2(6H)-THIONE/CN
E10           1     7-OXO-3A,12A-DIHYDROXY-5B-CHOLANOIC ACID/CN
E11           1     7-OXO-3A,12A-DIHYDROXY-5B-CHOLESTANOIC ACID
                    /CN
E12           1     7-OXO-3A,12A-DIHYDROXYCHOLAN-24-OIC ACID/CN

=> e 7-oxo-2-propylpoctanoic acid/cn
E1            1     7-OXO-2-PHENYL-4,7-DIHYDROTHIENO(3,2-B)PYRIDINE-6-CARBONITRI
                    LE/CN
E2            1     7-OXO-2-PHENYLAMINO-7H-PYRIDO(2,3-D)PYRIMIDIN-8-YLACETIC ACI
                    D METHYL ESTER/CN
E3            0 --> 7-OXO-2-PROPYLPOCTANOIC ACID/CN
E4            1     7-OXO-20-EPIMINOVINCININE/CN
E5            1     7-OXO-24-S,25-EPOXYCHOLESTEROL/CN
E6            1     7-OXO-3-OXABICYCLO(3.3.0)OCTANE/CN
E7            1     7-OXO-3-PHENYLTHIAZOLO(4,5-D)PYRIMIDINE-2(6H)-THIONE/CN
E8            1     7-OXO-3A,12A-DIHYDROXY-5B-CHOLANOIC ACID/CN
E9            1     7-OXO-3A,12A-DIHYDROXY-5B-CHOLESTANOIC ACID
                    /CN
E10           1     7-OXO-3A,12A-DIHYDROXYCHOLAN-24-OIC ACID/CN
E11           1     7-OXO-3A-HYDROXYCHOLAN-24-OIC ACID/CN
E12           1     7-OXO-4,5,6,7-TETRAHYDROBENZIMIDAZOLE-1-CARBOXYLIC ACID TERT
                    -BUTYL ESTER/CN

=> logoff hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                4.50       4.71

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:49:24 ON 04 SEP 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 13:54:52 ON 04 SEP 2007
FILE 'REGISTRY' ENTERED AT 13:54:52 ON 04 SEP 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	4.50	4.71

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10564720\10564720 try 1.str





chain nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-2 2-3 2-7 3-4 4-5 5-6 5-10 7-8 8-9
exact/norm bonds :
5-10
exact bonds :
1-2 2-3 2-7 3-4 4-5 5-6 7-8 8-9

Hydrogen count :
2:>= minimum 1 3:>= minimum 2 7:>= minimum 2 8:>= minimum 2 9:>= minimum 3
Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam
SAMPLE SEARCH INITIATED 13:55:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23371 TO ITERATE

8.6% PROCESSED 2000 ITERATIONS 0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 458271 TO 476569
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1 sss full
FULL SEARCH INITIATED 13:55:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 464717 TO ITERATE

100.0% PROCESSED 464717 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.06

L3 13 SEA SSS FUL L1

=> d scan

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentanoic acid, 4-hydroxy-2-propyl-, (R*,S*)- (9CI)
MF C8 H16 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenehexanoic acid, δ-[[(1,1-dimethylethoxy)carbonyl]amino]-
γ-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-α-propyl-,
[αR-(αR*,γS*,δS*)]- (9CI)
MF C26 H45 N O5 Si



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentanoic-3,3,4,4,5,5,5-d7 acid, 2-(2-hydroxypropyl)- (9CI)
MF C8 H9 D7 O3



L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 7-hydroxy-2-propyl-, (2R,7S)- (9CI)
MF C11 H22 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanoic acid, 4-ethoxy-5-oxo-2-propyl- (8CI)
MF C11 H20 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanoic acid, 4-butoxy-5-oxo-2-propyl- (8CI)
MF C13 H24 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentanoic acid, 4-hydroxy-2-propyl-, (R*,R*)- (9CI)
MF C8 H16 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentonic acid, 2,3-dideoxy-2-propyl- (9CI)
MF C8 H16 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenehexanoic acid, δ-[[(1,1-dimethylethoxy)carbonyl]amino]-γ-hydroxy-α-propyl-, [αR-(αR*,γS*,δS*)]- (9CI)
MF C20 H31 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 7-hydroxy-2-propyl-, (2R,7R)- (9CI)
MF C11 H22 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanoic acid, 4-hydroxy-5-oxo-2-propyl-, semicarbazone (6CI)
MF C10 H19 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanoic acid, 4-ethoxy-5-oxo-2-propyl-, 5-[(2,4-dinitrophenyl)hydrazone] (8CI)
MF C17 H24 N4 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentanoic acid, 4-hydroxy-2-propyl- (9CI)
MF C8 H16 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	177.95	178.16

FILE 'CAPLUS' ENTERED AT 13:57:02 ON 04 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 3 Sep 2007 (20070903/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> l3
L4          95 L3

=> save temp l4 oxyacidfnds/a
ANSWER SET L4 HAS BEEN SAVED AS 'OXYACIDFNDS/A'

=> l3/prep
           95 L3
      4455634 PREP/RL
L5          8 L3/PREP
                (L3 (L) PREP/RL)

=> d l5 4-8 ti

L5   ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of peptide HIV protease inhibitors

L5   ANSWER 5 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Pharmacokinetic aspects of drug teratogenesis:  species differences and
     structure-activity relationships of the anticonvulsant valproic acid

L5   ANSWER 6 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Metabolic fate of valproic acid in the rhesus monkey.  Formation of a
     toxic metabolite, 2-n-propyl-4-pentenoic acid

L5   ANSWER 7 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Synthesis of α-alkyl-γ-alkoxy-γ-acetylbutyric acid
     esters, and some of their reactions

L5   ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of δ-hydroxy-γ-lactones


=> d l5 1-8 ti Fbib abs

L5   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of branched carboxylic acid compound and use thereof
AN   2005:55187  CAPLUS
DN   142:134202
TI   Preparation of branched carboxylic acid compound and use thereof
IN   Imawaka, Haruo; Hasegawa, Tomoyuki; Sakuyama, Shigeru; Kawanaka, Yasufumi;
     Akiyama, Tsutomu; Hoshikawa, Masamitsu; Matsuda, Saiko
PA   Ono Pharmaceutical Co., Ltd., Japan
SO   PCT Int. Appl., 75 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------          ----   --------    --------------------   --------
```

PI WO 2005005366 A1 20050120 WO 2004-JP10366 20040714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2003-274988 A 20030715
EP 1650182 A1 20060426 EP 2004-747782 20040714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2003-274988 A 20030715
WO 2004-JP10366 W 20040714
US 2007167522 A1 20070719 US 2006-564720 20060117
JP 2003-274988 A 20030715
WO 2004-JP10366 W 20040714
OS MARPAT 142:134202
GI



I

AB A branched alkanoic acid represented by the general formula (I) (wherein R1 = optionally protected hydroxy or oxo; a wavy line indicates α configuration, β configuration, or a mixture of these in an arbitrary proportion; n = an integer of 1 to 3; m = an integer of 0 to 10, provided that two or more R1's are not bonded to the same carbon atom other than the terminal carbon atoms), a salt of the compound, or a prodrug of either is prepared The compound I is effective in, e.g., improving the function of astrocytes. It is useful as a preventive and/or therapeutic agent for brain infarction or nerve function disorders after brain infarction and for neurodegenerative diseases such as Parkinson's disease, Parkinson's syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease. Thus, a solution of 31 g (4S)-N-[(2R)-7-oxo-2-propyloctanoyl]-4-isopropyloxazolidin-2-one in 310 mL THF and 31 mL H2O was treated with 45.3 mL 30 weight% H2O2 at 6° and then dropwise with 100 mL 2 M aqueous LiOH at 5°, stirred at 24° for 3 h, treated dropwise with 300 mL 2 M NaNO2, stirred at 26° for 1 h to give, after workup and silica gel chromatog., (2R)-7-oxo-2-propyloctanoic acid (II). II at 30 μmol/L in vitro significantly reduced cellular S100β protein in astrocytes from 2,177.0±147.74 to 1,489.0±37.84 (ng/mg). Pharmaceutical formulations, e.g. tablet containing II, were prepared
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of peptide HIV protease inhibitors containing guanidine
AN 1994:164904 CAPLUS

DN 120:164904
TI Preparation of peptide HIV protease inhibitors containing guanidine
IN Gleason, John Gerald; Lum, Robert Thomas
PA SmithKline Beecham Corp., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9309132	A1	19930513	WO 1992-US9402	19921030
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
				US 1991-786435	A2 19911101
	ZA 9208396	A	19930512	ZA 1992-8396	19921030
				US 1991-786435	A 19911101
	AU 9230691	A	19930607	AU 1992-30691	19921030
				US 1991-786435	A 19911101
				WO 1992-US9402	A 19921030
	EP 610431	A1	19940817	EP 1992-924217	19921030
	R: BE, CH, DE, FR, GB, IT, LI, NL				
				US 1991-786435	A 19911101
				WO 1992-US9402	W 19921030
	JP 07501056	T	19950202	JP 1992-508659	19921030
				US 1991-786435	A 19911101
				WO 1992-US9402	W 19921030

OS MARPAT 120:164904
GI

Q1= 

AB AD1D2MNRC(:Z)NRR1 [R = H, alkyl, CH2Ph; R1 = R7, R7CO, R7O2C, R7OCHR8CO, ANRCHR5CO; Z = O, NR2; R2 = H, cyano, RCO; D1, D2 = J1CHR5CO, null; J1, J2 = NH, CH2, O; M = NRCHR3CHQ1CHQ2CR4Q3COE, Q1; E = J2CHR6CO; Q1, Q2, Q3 = H, NH2, OH; V = N, C; Y = N, O, S; R3, R4 = H, (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, cycloalkyl, etc.; R5, R6 = (substituted) alkyl, etc.; R7, R8 = H, alkyl, cycloalkyl, etc.; R9 = O, S, H2; A = H, (substituted) aryl, heterocyclyl, etc.; k = 0, 1], were prepared Thus, (2R,4S,5S)-2-phenylmethyl-4-(t-butyldimethylsilyloxy)-5-(t-butoxycarbonyl)amino-6-phenylhexanoylvaline (preparation given) was condensed with carbobenzyloxyguanidine using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH2Cl2 to give 80% coupling product, which was treated with Bu4NF in THF to give 35% N-benzyloxycarbonyl, N'-[(2R,4S,5S)-2-phenylmethyl-4-hydroxy-5-(t-butoxycarbonyl)amino-6-phenylhexanoyl-5-valyl]guanidine. Title compds. inhibit HIV-1 with Ki = 0.1-2.5 μM.

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays
AN 1992:482903 CAPLUS
DN 117:82903
TI Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1

protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected T-cell assays

AU Dreyer, Geoffrey B.; Lambert, Dennis M.; Meek, Thomas D.; Carr, Thomas J.; Tomaszek, Thaddeus A., Jr.; Fernandez, Annabellee V.; Bartus, Henry; Cacciavillani, Emilio; Hassell, Anne M.; et al.

CS Dep. Med. Chem., SmithKline Beecham Pharm., King of Prussia, PA, 19406, USA

SO Biochemistry (1992), 31(29), 6646-59
CODEN: BICHAW; ISSN: 0006-2960

DT Journal

LA English

AB Analogs of peptides ranging in size from three to six amino acids and containing the hydroxyethylene dipeptide isosteres PheΨGly, PheΨAla, PheΨNorVal, PheΨLeu, and PheΨPhe, where Ψ denotes replacement of CONH by (S)-CH(OH)CH2, were synthesized and studied as HIV-1 protease inhibitors. Inhibition consts. (Ki) with purified HIV-1 protease depend strongly on the isostere in the order PheΨGly > PheΨAla > PheΨNorVal > PheΨLeu > PheΨPhe and decrease with increasing length of the peptide analogs, converging to a value of 0.4 nM. Ki Values are progressively less dependent on inhibitor length as the size of the P1' side chain within the isostere increases. The structures of HIV-1 protease complexed with the inhibitors Ala-Ala-X-Val-Val-OMe, where X is PheΨGly, PheΨAla, PheΨNorVal, and PheΨPhe, have been determined by x-ray crystallog. (resolution 2.3-3.2 Å). The crystals exhibit symmetry consistent with space group P61 with strong noncrystallog. 2-fold symmetry, and the inhibitors all exhibit 2-fold disorder. The inhibitors bind in similar conformations, forming conserved hydrogen bonds with the enzyme. The PheΨGly inhibitor adopts an altered conformation that places its P3' valine side chain partially in the hydrophobic S1' pocket, thus suggesting an explanation for the greater dependence of the Ki value on inhibitor length in the PheΨGly series. From the kinetic and crystallog. data, a minimal inhibitor model for tight-binding inhibition is derived in which the enzyme substitutes S2-S2' are optimally occupied. The Ki values for several compds. are compared with their potencies as inhibitors of proteolytic processing in T-cell cultures chronically infected with HIV-1 (MIC values) and as inhibitors of acute infectivity (IC50 values). There is a rank-order correspondence, but a 20-1000-fold difference, between the values of Ki and those of MIC or IC50. IC50 values can approach those of Ki but are highly dependent on the conditions of the acute infectivity assay and are influenced by physicochem. properties of the inhibitors such as solubility

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of peptide HIV protease inhibitors

AN 1991:656667 CAPLUS

DN 115:256667

TI Preparation of peptide HIV protease inhibitors

IN Dreyer, Geoffrey Bainbridge; Carr, Thomas Joseph

PA SmithKline Beecham Corp., USA

SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9110442	A1	19910725	WO 1991-US178		19910109
	W: JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE					
				US 1990-462669	A	19900109
				US 1990-469891	A	19900123
	JP 05503703	T	19930617	JP 1991-503872		19910109
				US 1990-462669	A	19900109

			US 1990-469891	A	19900123
			WO 1991-US178	W	19910109
EP 594586	A1	19940504	EP 1991-903689		19910109
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE					
			US 1990-462669	A	19900109
			US 1990-469891	A	19900123
			WO 1991-US178	W	19910109

OS MARPAT 115:256667

AB ACbDcMXeYZ [A = H, Me3CO2CNH, PhCH2O2CNH, NR1R2,R2CONR1; when a = b = c = 0 and Y = band A = H, Me3CO2C, PhCH2O2C, R2,R2CO; C,D = Ala, β-Ala, D-Ala, Phe, Phg, Val; M = NHCH(CH2Ph)CH(OH)CH2CHRCO; R = alkyl, alkenyl, PhCH2; R1,R2 = H, alkyl; X = Ala, Ile, Leu, Val; Y = groups cited for X, band; Z = H, CO2R4, CONR1R4, COR1, CH2OR4, CH2O2CR2; R4 = H, (cyclo)alkyl, phenylalkyl, hydroxyalkyl, aminoalkyl, etc.; b, c, e = 0, 1 (b ≠ c = 0)] were prepared Thus, Me3CO2CNHCH(CH2Ph)CHO (preparation given) was condensed with CH2:CHCH2CH2MgBr and the product converted in 7 steps to Me3CO2CNHCH(CH2Ph)CH(OSiMe2CMe3)CH2CHPrCO2H which was condensed, in turn, with H-Val-Val-OMe and PhCH2O2C-ala-OH to give, after deprotection, PhCH2O2C-M-Val-Val-OMe (R = Pr) a the latter had Ki of 6.8 + 10-4 μM for inhibition of HIV protease in vitro.

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Pharmacokinetic aspects of drug teratogenesis: species differences and structure-activity relationships of the anticonvulsant valproic acid

AN 1990:584217 CAPLUS

DN 113:184217

TI Pharmacokinetic aspects of drug teratogenesis: species differences and structure-activity relationships of the anticonvulsant valproic acid

AU Nau, Heinz

CS Inst. Toxicol. Embryopharmacol., Free Univ. Berlin, Berlin, D-1000/33, Germany

SO Acta Pharmaceutica Jugoslavica (1990), 40(2, Supp. 1), 291-300
CODEN: APJUA8; ISSN: 0001-6667

DT Journal

LA English

AB A direct teratol. effect will depend on the concentration-time relationship of the drug or its active metabolite(s) in the embryo/fetus during sensitive stages of gestation. Transplacental pharmacokinetic studies are therefore of great importance for the interpretation of interspecies differences, structure-activity relationships and mechanistic studies in teratogenesis. The antiepileptic drug valproic acid and a number of metabolites and analogous substances will be used to demonstrate the significance of this concept. The teratogenic response was found to be highly structure-specific and depended on the exposure of the embryo to the parent drug and not metabolites. Peak concns. and not AUC values in maternal plasma and the embryo correlated with the potency of valproic acid to elicit neural tube defects in the mouse (exencephaly). Higher doses and concns. of valproic acid were needed in exptl. animals to produce a significant teratogenic response than in the human. Also the pattern of malformations showed great species differences: neural tube defects were produced by valproic acid in the human (spina bifida) and mouse (exencephaly), but not in the other species investigated. In conclusion, taking pharmacokinetic considerations into account, the sensitivity of the embryo decreases in the following sequence: human > monkey > mouse > rat.

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid

AN 1986:545594 CAPLUS

DN 105:145594

TI Metabolic fate of valproic acid in the rhesus monkey. Formation of a

toxic metabolite, 2-n-propyl-4-pentenoic acid
AU Rettenmeir, Albert W.; Gordon, W. Perry; Prickett, Kathryn S.; Levy, Rene H.; Lockard, Joan S.; Thummel, Kenneth E.; Baillie, Thomas A.
CS Dep. Med. Chem., Univ. Washington, Seattle, WA, 98195, USA
SO Drug Metabolism and Disposition (1986), 14(4), 443-53
CODEN: DMDSAI; ISSN: 0090-9556
DT Journal
LA English
AB The metabolic fate of an i.v. bolus dose (13.5 mg/kg) of valproic acid (VPA) [99-66-1] was studied in adult male rhesus monkeys. Renal excretion proved to be the major route of elimination of the drug and a total of 17 metabolites, accounting collectively for some 82% of the administered dose, were identified in urine by GC-MS techniques. Many of these metabolites were present largely in the form of glucuronide conjugates, as was VPA itself. The principal pathways of VPA biotransformation were, in order of decreasing quant. importance, ester glucuronide formation, ω-oxidation, β-oxidation and (ω-1)-hydroxylation. In addition 3 mono-unsatd. metabolites, identified as (E)-Δ2- [33786-47-9], (E)-Δ3- [80382-68-9] and Δ4-VPA [1575-72-0] were detected in both plasma and urine. Quant. anal. of these unsatd. VPA metabolites indicated that the Δ4 olefin, which is known to be a potent hepatotoxic agent, was the predominant isomer of the group.

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of α-alkyl-γ-alkoxy-γ-acetylbutyric acid esters, and some of their reactions
AN 1971:463067 CAPLUS
DN 75:63067
TI Synthesis of α-alkyl-γ-alkoxy-γ-acetylbutyric acid esters, and some of their reactions
AU Zalinyan, M. G.; Saakyan, L. A.; Arutyunyan, V. S.; Dangyan, M. T.
CS Erevan. Gos. Univ., Erevan, USSR
SO Armyanskii Khimicheskii Zhurnal (1971), 24(3), 237-44
CODEN: AYKZAN; ISSN: 0515-9628
DT Journal
LA Russian
GI For diagram(s), see printed CA Issue.
AB α-Alkyl-γ-alkoxy-γ-acetylbutyric acid esters (I) were prepared by reaction of α-alkyl-γ-acetylbutyrolactones (II) (R = Et, Pr, Bu, iso-Bu, iso-C5H11) with SOCl2 in the presence of an alc. I hydrolyzed with KOH gave α-alkyl-γ-alkoxy-γ-acetylbutyric acids. These heated with SOCl2 gave 3-alkyl-5-alkoxy-6-methyl-3,4-dihydro-α-pyrones (III) (R as above, R1 = Et, Bu). I with an equimol. amount PCl5 gave alkyl alkyl(β-alkoxy-γ-chlorocrotyl)acetates.

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of δ-hydroxy-γ-lactones
AN 1960:1677 CAPLUS
DN 54:1677
OREF 54:283f-i,284a-d
TI Preparation of δ-hydroxy-γ-lactones
AU Dangyan, M. T.; Zalinyan, M. G.
SO Nauch. Trudy Erevan. Gosudarst. Univ., Ser. Khim. Nauk (1956), 53(No. 3), 15-24;Russian summary, 25-6
DT Journal
LA Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. preceding abstract To 160 ml. absolute EtOH was added 6.3 g. Na and then 55.40 g. PrCH(CO2Et)2, the mixture cooled, stirred, 34.5 g. MeCCl:CHCH2Cl (I) added dropwise and heated 6 hrs. on a water bath. After removing the alc., 150 ml. H2O was added, the oily layer separated, the H2O layer extracted

with Et2O and combined with the oily layer, washed with H2O, dried (Na2SO4) and distilled; the fraction b6 141-5° yielded 89.3% MeCCl:CHCH2C(CO2Et)2Pr (II), d20 1.0563, nD 1.4545, MRD 74.57. To 23.3 g. NaOH in 350 ml. EtOH, 56 g. II was added gradually and the whole refluxed 30-40 min., 100 ml. H2O added, alc. removed, 100 ml. 25% HCl added to the residue, the oily layer separated, the H2O layer extracted with Et2O, added to the oily layer, dried (Na2SO4 and the Et2O removed to yield 86.4% MeCCl:CHCH2C(CO2H)2Pr (III), m. 132-4°. III (39 g.) was heated to 170-80° until AcOH ceased to evolve, the product was distilled and the fraction b6-6.5 138-40° collected to give 89.3% MeCCl:CHCH2CH(Pr)CO2H (IV), a liquid insol. in H2O, d20 1.0593, nD 1.4653, MR 49.76. IV (9.5 g.) in 30 ml. HCO2H treated dropwise with 6.5 ml. 30% H2O2 in 20 ml. HCO2H, kept 16 hrs. at 40-5°, HCO2H removed and the mixture distilled in vacuo gave from the fraction b8 139-42° 82.92% MeCOCH.CH2.CH(Pr).CO.O (V), d20 1.0886, nD 1.4593, MR 42.7. To 0.35 g. V was added 0.22 g. H2NCONHNH2.HCl (VI) in H2O and 0.2 g. KOAc in alc., the solution allowed to stand 1 day, the precipitate filtered off, and washed with H2O then with Et2O to yield 75.6% semicarbazone, m. 183-5°. MeCCl:CHCH2CH(Bu)CO2H in 45 ml. 85% HCO2H treated with 10 ml. H2O2 and the mixture kept at 50-60° 20 hrs. with stirring gave 84.10% MeCOCH.CH2.CH(Bu).CO.O (VII), oil, insol. in H2O, b9-10 141-3°, d20 1.0534, nD 1.0554, MR 47.71; semicarbazone (prepared from 4.2 g. VII, 2.54 g. VI and 2.27 g. KOAc, yield 74.76%) m. 182-3°. iso-BuCH(CO2Et)2 (184.6 g.) in 290 ml. absolute alc., 19.71 g. Na and 107.3 g. I gave 71.3% iso-BuC(CO2Et)2CH2CH:CClMe (VIII), a liquid, insol. in H2O, b9 146-9°, d20 1.04406, nD 1.4553, MR 79.33. VIII (185 g.) was saponified with 76 g. NaOH to give 67.68% MeCCl:CHCH2C(Bu-iso)(CO2H)2 (IX), m. 96-9°; 102 g. IX heated until CO2 evolution ceased, and distilled gave from the 144-7°/8-9 m. fraction 89.8% MeCCl:CHCH2CH(iso-Bu)CO2H (X), liquid, insol. in H2O, d20 1.0403, nD 1.4642, MRD 54.42. X (20.51 g.) in 60 ml. glacial AcOH treated with 15-25 ml. 30% H2O2, the mixture heated 20-22 hrs. to 50-60° and distilled gave from the 135-8° fraction 82.6% MeCOCH.CH2.CH(Bu-iso).CO.O (XI), d20 1.0613, nD 1.4603, MR 47.602; semicarbazone (prepared from 0.47 g. XI, 0.25 g. of V and 0.23 g. KOAc, yield 73.7%) m. 170-1°. To 9 g. MeCCl:CHCH2CH(Am-iso)CO2H in 40 ml. glacial AcOH was added dropwise a mixture of 40 ml. glacial AcOH and 9.09 ml. H2O2, the mixture heated and distilled gave 86.2% oily MeCOCH.CH2.CH(Am-iso).CO.O (XII), b8 150-5° d20 1.0229, nD 1.4558, MR 52.49; semicarbazone (prepared from 4.8 g. XII, 2.7 g. V and 2.38 g. KOAc, yield 77.2%) m. 173-5°.

=> save temp all hdrxyestsrch/l
L# LIST L1-L5 HAS BEEN SAVED AS 'HDRXYESTSRCH/L'

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.34	212.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:07:20 ON 04 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 05:51:08 ON 05 SEP 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.42       0.42

FILE 'REGISTRY' ENTERED AT 05:52:14 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     4 SEP 2007  HIGHEST RN 946048-22-2
DICTIONARY FILE UPDATES:    4 SEP 2007  HIGHEST RN 946048-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e 2-propyloctanoic acid/cn
E1            1     2-PROPYLOCTADECANOIC ACID/CN
E2            1     2-PROPYLOCTANAL/CN
E3            1 --> 2-PROPYLOCTANOIC ACID/CN
E4            1     2-PROPYLOLCYCLOPENTANONE/CN
E5            1     2-PROPYLOXIRANE/CN
E6            1     2-PROPYLOXY-2,2-DI(4-FLUOROPHENYL)ACETIC ACID/CN
E7            1     2-PROPYLOXY-2-PHENYLACETOPHENONE/CN
E8            1     2-PROPYLPENT-4-ENAL/CN
E9            1     2-PROPYLPENTAETHOXYBIS(DIMETHYLSILOXY)PENTAPROPOXYPROPANE/CN
E10           1     2-PROPYLPENTAMIDE/CN
E11           1     2-PROPYLPENTANAL/CN
E12           1     2-PROPYLPENTANENITRILE/CN

=> e3
L1            1 "2-PROPYLOCTANOIC ACID"/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   31080-41-8  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Octanoic acid, 2-propyl- (8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2-Propyloctanoic acid
DR   161089-81-2
MF   C11 H22 O2
CI   COM
LC   STN Files:   BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM,
```

IMSPATENTS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.80	8.22

FILE 'CAPLUS' ENTERED AT 05:53:09 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l1
L2 9 L1

=> d l2

L2 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:48702 CAPLUS
DN 144:135155
TI Brain-targeted prodrugs for (optically active) 2-propyloctanoic acid and their compositions for improving astrocyte function and prophylactic and/or therapeutic treatment of nerve degeneration
IN Nakayama, Kosuke
PA Ono Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 41 pp.
CODEN: JKXXAF
DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006016318	A	20060119	JP 2004-193922	20040630
PRAI	JP 2004-193922		20040630		
OS	MARPAT 144:135155				

=> d l2 1-9 ti

L2 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Brain-targeted prodrugs for (optically active) 2-propyloctanoic acid and their compositions for improving astrocyte function and prophylactic and/or therapeutic treatment of nerve degeneration

L2 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Prodrugs for (optically active) 2-propyloctanoic acid, their compositions for improving astrocyte function, and prevention and/or treatment of neurodegenerative disease with the prodrugs

L2 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Teratogenic effects mediated by inhibition of histone deacetylases evidence from quant. structure activity relationships of valproic acid derivs.

L2 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Nerve regeneration promoters containing fatty acid compounds

L2 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of substituted lactams as inhibitors of aβ protein production

L2 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of valproate analogs as neuroprotectants

L2 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Side reactions in hydrocarboxylation of olefins

L2 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Radiation-initiated reaction of ethylene with carboxylic acids

L2 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gas-chromatographic analysis of branched carboxylic acids formed during the carboxylation of C6-10 α-alkenes

=> d l2 6 ti fbib abs

L2 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of valproate analogs as neuroprotectants
AN 1995:372897 CAPLUS
DN 122:160096
TI Preparation of valproate analogs as neuroprotectants
IN Ohuchida, Shuichi; Kishimoto, Kazuo; Tateishi, Narito; Ohno, Hiroyuki
PA Ono Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 70 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 632008	A1	19950104	EP 1994-108330	19940530

EP 632008	B1	19980204			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
AT 163006	T	19980215	AT 1994-108330		19940530
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
ES 2113574	T3	19980501	ES 1994-108330		19940530
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
CA 2124784	A1	19941202	CA 1994-2124784		19940531
CA 2124784	C	20030107			
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
JP 07316092	A	19951205	JP 1994-140957		19940531
JP 2756756	B2	19980525			
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
CN 1100408	A	19950322	CN 1994-106203		19940601
CN 1083419	B	20020424			
			JP 1993-154331	A	19930601
			JP 1994-80982	A	19940328
KR 225299	B1	19991015	KR 1994-12261		19940601
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
US 6201021	B1	20010313	US 1996-681482		19960723
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			US 1994-252642	B1	19940601
JP 09118644	A	19970506	JP 1996-216932		19960731
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			JP 1994-140957	A3	19940531
JP 10204023	A	19980804	JP 1998-32255		19980129
JP 2935110	B2	19990816			
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			JP 1996-216932	A3	19940531
JP 10324626	A	19981208	JP 1998-155577		19980604
JP 3195581	B2	20010806			
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			JP 1996-216932	A3	19940531
CN 1322524	A	20011121	CN 2000-127088		20000908
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
US 2003096802	A1	20030522	US 2002-194247		20020715
US 7176240	B2	20070213			
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			US 1994-252642	B1	19940601

			US 1996-681482	A3	19960723
			US 2000-661054	B1	20000913
US 2005261371	A1	20051124	US 2005-192004		20050729
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			US 1994-252642	B1	19940601
			US 1996-681482	A3	19960723
			US 2000-661054	B1	20000913
			US 2002-194247	A1	20020715
US 2005267167	A1	20051201	US 2005-192002		20050729
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			US 1994-252642	B1	19940601
			US 1996-681482	A3	19960723
			US 2000-661054	B1	20000913
			US 2002-194247	A1	20020715
US 2005267168	A1	20051201	US 2005-192003		20050729
			JP 1993-154331	A	19930601
			JP 1993-301067	A	19931105
			JP 1994-80982	A	19940328
			US 1994-252642	B1	19940601
			US 1996-681482	A3	19960723
			US 2000-661054	B1	20000913
			US 2002-194247	A1	20020715

OS MARPAT 122:160096

AB R1CH2CHPrCOR2 (I; R1 = fluoroalkyl; R2 = OH, alkoxy, NH2, etc.) and Et(CH2)nCR5R11COR6 [II; R5 = CH2R7, (cyclo)alkyl, alkoxy, Ph, etc.; R6 = OH, alkoxy, NH2, etc.; R7 = (CH2)mF; R11 = H or Cl; R5R11 = alkylidene; n = 0 or 1; m = 4-6] were prepared Thus, HO(CH2)4CHO was condensed with Ph3P:CPrCO2Me and the product converted in 3 steps to F2CH(CH2)4CHPrCO2Me. Data for inhibition of reactive astrocyte-induced diminution of GABAA receptor response by I and II in vitro were given.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.12	22.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:02:14 ON 05 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 06:11:41 ON 05 SEP 2007
FILE 'CAPLUS' ENTERED AT 06:11:41 ON 05 SEP 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.12	22.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.12	22.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'REGISTRY' ENTERED AT 06:11:54 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2
DICTIONARY FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10564720\10564720 2-propyl octanoic.str



chain nodes :
1 2 3 4 5 6 7 8 9 11 12
chain bonds :
1-2 2-3 2-7 3-4 4-5 5-6 6-11 7-8 8-9 11-12
exact bonds :
1-2 2-3 2-7 3-4 4-5 5-6 6-11 7-8 8-9 11-12

Hydrogen count :
2:>= minimum 1 7:>= minimum 2 8:>= minimum 2 9:>= minimum 3

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
11:CLASS 12:CLASS

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l3 sss sam
SAMPLE SEARCH INITIATED 06:12:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23647 TO ITERATE

8.5% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 463738 TO 482142
PROJECTED ANSWERS: 30 TO 442

L4 1 SEA SSS SAM L3

=> d scan

L4 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 10-Undecenoic acid, 2-propyl- (9CI)
MF C14 H26 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l3 sss full
FULL SEARCH INITIATED 06:12:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 470331 TO ITERATE

100.0% PROCESSED 470331 ITERATIONS 194 ANSWERS
SEARCH TIME: 00.00.05

L5 194 SEA SSS FUL L3

=> d scan

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 8-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 3-hydroxy-3-(2-propenyl)-2-propyl- (9CI)
MF C16 H30 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 3-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanedioic acid, 2-propyl-, polymer with N,N'-bis(2-aminoethyl)-1,2-ethanediamine and decanedioic acid (9CI)
MF (C13 H24 O4 . C10 H18 O4 . C6 H18 N4)x
CI PMS, COM

CM 1



CM 2



CM 3



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanedioic acid, 2,9-dipropyl- (9CI)
MF C16 H30 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 2-propyl-, sodium salt (9CI)
MF C13 H26 O2 . Na



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, sodium salt, (2R)- (9CI)
MF C11 H22 O2 . Na

Absolute stereochemistry. Rotation (-).



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexadecanoic acid, 2-propyl-, sodium salt (9CI)
MF C19 H38 O2 . Na



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (βR)-β-aminobenzenepropanol (1:1) (9CI)
MF C11 H22 O2 . C9 H13 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 7-methyl-2-propyl- (9CI)
MF C14 H28 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H40 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 8-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 2-propyl-, sodium salt (6CI, 9CI)
MF C17 H34 O2 . Na



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 5-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanedioic acid, 2-propyl-, polymer with N,N'-bis(2-aminoethyl)-1,2-ethanediamine and decanedioic acid, (diphosphate) (9CI)
MF (C13 H24 O4 . C10 H18 O4 . C6 H18 N4)x . x H4 O7 P2

CM 1



CM 2

CM 3



CM 4



CM 5



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 10-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanedioic acid, 2-pentyl-3-propyl-, diammonium salt (9CI)
MF C12 H22 O4 . 2 H3 N





L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2S)-
MF C11 H22 O2

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9-fluoro-2-propyl- (9CI)
MF C12 H23 F O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (αR)-α,4-dimethylbenzenemethanamine (1:1) (9CI)
MF C11 H22 O2 . C9 H13 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 4-methyl-2-propyl- (9CI)
MF C13 H26 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with cycloheptanamine (1:1) (9CI)
MF C11 H22 O2 . C7 H15 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 7-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 2-propyl- (6CI, 7CI, 8CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 6-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 3-(2-propenylidene)-2-propyl- (9CI)
MF C14 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 12-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanedioic acid, 2-propyl-, compd. with cyclohexanamine (1:2) (9CI)
MF C11 H20 O4 . 2 C6 H13 N

CM 1



CM 2



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanedioic acid, 2,7-dipropyl- (9CI)
MF C14 H26 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9-fluoro-2-propyl-, sodium salt (9CI)
MF C12 H23 F O2 . Na



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 7-oxo-2-propyl-, sodium salt, (2R)- (9CI)
MF C11 H20 O3 . Na

Absolute stereochemistry.



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 2-propyl-, sodium salt (9CI)
MF C12 H24 O2 . Na



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (1S,2R)-2-[(phenylmethyl)amino]cyclohexanemethanol (1:1) (9CI)
MF C14 H21 N O . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 5-methyl-2-propyl- (9CI)
MF C14 H28 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Valeric acid, 2-dihydrocitronellyl- (5CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 6-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 2-propyl- (6CI, 9CI)
MF C17 H34 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 3-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanedioic acid, 2-propyl-, disodium salt (7CI)
MF C15 H28 O4 . 2 Na





L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 8-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 2-propyl-, (+)- (9CI)
MF C13 H26 O2

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanedioic acid, 2-propyl-, 9-tetracontyl ester (9CI)
MF C52 H102 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9,9,9-trifluoro-2-propyl- (9CI)
MF C12 H21 F3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (βS)-β-aminobenzeneethanol (1:1) (9CI)
MF C11 H22 O2 . C8 H11 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 5-methyl-2-propyl- (9CI)
MF C12 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with cyclohexanamine (1:1) (9CI)
MF C11 H22 O2 . C6 H13 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 5-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,5,8,9-Dodecanetetracarboxylic acid (7CI, 8CI, 9CI)
MF C16 H26 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 4-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 2-propyl- (9CI)
MF C12 H24 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 194 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 10-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> save temp l5 prpoctacid/a
ANSWER SET L5 HAS BEEN SAVED AS 'PRPOCTACID/A'

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	174.35	196.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:15:41 ON 05 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 06:37:06 ON 05 SEP 2007
FILE 'REGISTRY' ENTERED AT 06:37:06 ON 05 SEP 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	174.35	196.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10564720\10564720 oxy(o) 2-propyl octanoic.str





chain nodes :
1 2 3 4 5 6 7 8 9 11 12 14 15 17 18 19 20 21 22 24 25 26 27 28
chain bonds :

1-2 2-3 2-7 3-4 3-14 3-15 4-5 4-17 4-18 5-6 5-19 5-20 6-11 6-21 6-22
7-8 8-9 11-12 11-24 11-25 12-26 12-27 12-28
exact/norm bonds :
3-14 3-15 4-17 4-18 5-19 5-20 6-21 6-22 11-24 11-25 12-26 12-27 12-28
exact bonds :
1-2 2-3 2-7 3-4 4-5 5-6 6-11 7-8 8-9 11-12

G1:H,O

Hydrogen count :
2:>= minimum 1 7:>= minimum 2 8:>= minimum 2 9:>= minimum 3
Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
11:CLASS 12:CLASS 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 H,O

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 05:51:08 ON 05 SEP 2007)

FILE 'REGISTRY' ENTERED AT 05:52:14 ON 05 SEP 2007
E 2-PROPYLOCTANOIC ACID/CN
L1 1 E3

FILE 'CAPLUS' ENTERED AT 05:53:09 ON 05 SEP 2007
L2 9 L1

FILE 'REGISTRY' ENTERED AT 06:11:54 ON 05 SEP 2007
L3 STRUCTURE UPLOADED
L4 1 SEARCH L3 SSS SAM
L5 194 SEARCH L3 SSS FULL
SAVE TEMP L5 PRPOCTACID/A
L6 STRUCTURE UPLOADED

=> search l6 subset=l5 sss sam

SAMPLE SUBSET SEARCH INITIATED 06:38:39 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.03

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 22 TO 418
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 22 TO 418

L7 11 SEA SUB=L5 SSS SAM L6

=> dscan
0 DSCAN
L8 0 DSCAN

=> d scan l7

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 10-Undecenoic acid, 2-propyl- (9CI)
MF C14 H26 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI)
MF C12 H23 N . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (αR)-α-methylbenzenemethanamine (1:1) (9CI)
MF C11 H22 O2 . C8 H11 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 11-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexadecanoic acid, 2-propyl-, sodium salt (9CI)
MF C19 H38 O2 . Na



L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanedioic acid, 5-cyclohexyl-3-hexyl-2-propyl- (9CI)
MF C21 H38 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 2-propyl- (6CI, 7CI, 8CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanedioic acid, 2,7-dipropyl-, diammonium salt (9CI)
MF C14 H26 O4 . 2 H3 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 14-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 8-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 11 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9,9-difluoro-2-propyl- (9CI)
MF C12 H22 F2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> search l6 subset=l5 sss full
FULL SUBSET SEARCH INITIATED 06:40:55 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 194 TO ITERATE

100.0% PROCESSED 194 ITERATIONS 175 ANSWERS
SEARCH TIME: 00.00.02

L9 175 SEA SUB=L5 SSS FUL L6

=> d scan

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 9-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexanedioic acid, 5-cyclohexyl-3-hexyl-2-propyl- (9CI)
MF C21 H38 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 5-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9,9-difluoro-2-propyl-, sodium salt (9CI)
MF C12 H22 F2 O2 . Na



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanedioic acid, 2-pentyl-3-propyl- (9CI)
MF C12 H22 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 3-[hydroxy(phenylmethyl)phosphinyl]-2-propyl- (9CI)
MF C18 H29 O4 P



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (αR)-α-methyl-1-naphthalenemethanamine (1:1) (9CI)
MF C12 H13 N . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 5-methyl-2-propyl- (9CI)
MF C14 H28 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with 2,2,6,6-tetramethyl-4-piperidinol (1:1) (9CI)

MF C11 H22 O2 . C9 H19 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 7-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexadecanedioic acid, 2-propyl- (9CI)
MF C19 H36 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 5-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 2-propyl- (6CI, 9CI)
MF C15 H30 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 11-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, sodium salt (9CI)
MF C11 H22 O2 . Na



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 7-hydroxy-2-propyl-, (2R,7S)- (9CI)
MF C11 H22 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 3-methyl-2-propyl- (9CI)
MF C12 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (1S,2R)-2-[(phenylmethyl)amino]cyclohexanemethanol (1:1) (9CI)
MF C14 H21 N O . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 4-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, lithium salt, (2R)- (9CI)
MF C11 H22 O2 . Li

Absolute stereochemistry. Rotation (-).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 4-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexadecanoic acid, 2-propyl- (6CI, 7CI, 9CI)
MF C19 H38 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 11-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,7,10-Octadecanetricarboxylic acid, polymer with 1,4-benzenedicarboxylic acid, (2E)-2-butenedioic acid, α,α'-[(1-methylethylidene)di-4,1-phenylene]bis[ω-hydroxypoly(oxy-1,2-ethanediyl)] and α,α'-[(1-methylethylidene)di-4,1-phenylene]bis[ω-hydroxypoly[oxy(methyl-1,2-ethanediyl)]] (9CI)
MF (C21 H38 O6 . C8 H6 O4 . C4 H4 O4 . (C3 H6 O)n (C3 H6 O)n C15 H16 O2 . (C2 H4 O)n (C2 H4 O)n C15 H16 O2)x
CI PMS

CM 1



CM 2



CM 3



CM 4

Double bond geometry as shown.



CM 5



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanedioic acid, 2,7-dipropyl- (9CI)
MF C14 H26 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 7-methyl-2-propyl- (9CI)
MF C12 H24 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (1S,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (1:1) (9CI)
MF C20 H31 N . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 6-methyl-2-propyl- (9CI)
MF C13 H26 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with α-phenylbenzenemethanamine (1:1) (9CI)
MF C13 H13 N . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 10-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanedioic acid, 2-propyl- (7CI, 8CI)
MF C12 H22 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):30

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 10-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanedioic acid, 2-propyl- (7CI)
MF C15 H28 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 6-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 9,9,9-trifluoro-2-propyl-, sodium salt (9CI)
MF C12 H21 F3 O2 . Na



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanedioic acid, 2-propyl-, 9-tetracontyl ester (9CI)
MF C52 H102 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 2-propyl-, sodium salt (9CI)
MF C12 H24 O2 . Na



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (αS)-α-methyl-1-naphthalenemethanamine (1:1) (9CI)
MF C12 H13 N . C11 H22 O2

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 6-methyl-2-propyl- (9CI)
MF C14 H28 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with 2-methoxybenzeneethanamine (1:1) (9CI)
MF C11 H22 O2 . C9 H13 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 8-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Hexadecanedioic acid, 2-propyl-, compd. with phenylmethyl carbamimidothioate (1:2) (9CI)
MF C19 H36 O4 . 2 C8 H10 N2 S

CM 1



CM 2



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 6-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octadecanoic acid, 2-propyl-, thallium(1+) salt (9CI)
MF C21 H42 O2 . Tl



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Pentadecanoic acid, 12-methyl-2-propyl- (9CI)
MF C19 H38 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 8,8-difluoro-2-propyl- (9CI)
MF C11 H20 F2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 8-hydroxy-2-propyl-, (2R)- (9CI)
MF C11 H22 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 4-methyl-2-propyl- (9CI)
MF C12 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (βS)-β-aminobenzenepropanol (1:1) (9CI)
MF C11 H22 O2 . C9 H13 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Undecanoic acid, 5-methyl-2-propyl- (9CI)
MF C15 H30 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H40 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tridecanoic acid, 5-methyl-2-propyl- (9CI)
MF C17 H34 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,5,10,11-Tetradecanetetracarboxylic acid (9CI)
MF C18 H30 O8



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tetradecanoic acid, 12-methyl-2-propyl- (9CI)
MF C18 H36 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Decanoic acid, 2-propyl-, (+)- (9CI)
MF C13 H26 O2

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (αR)-α-methylbenzenemethanamine (1:1) (9CI)
MF C11 H22 O2 . C8 H11 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (+).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 6-methyl-2-propyl- (9CI)
MF C12 H24 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with (βR)-β-aminobenzeneethanol (1:1) (9CI)
MF C11 H22 O2 . C8 H11 N O

CM 1

Absolute stereochemistry. Rotation (-).



CM 2

Absolute stereochemistry. Rotation (-).



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nonanoic acid, 7-methyl-2-propyl- (9CI)
MF C13 H26 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Octanoic acid, 2-propyl-, (2R)-, compd. with cyclohexanamine (1:1) (9CI)
MF C11 H22 O2 . C6 H13 N

CM 1

Absolute stereochemistry. Rotation (-).



CM 2



L9 175 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Dodecanoic acid, 3-methyl-2-propyl- (9CI)
MF C16 H32 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	224.90	247.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'CAPLUS' ENTERED AT 06:43:57 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> 19
L10 157 L9

=> hydroxy?
L11 1289710 HYDROXY?

=> l10 and l11
L12 26 L10 AND L11

=> d l12 16-26 ti

L12 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of valproate analogs as neuroprotectants

L12 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Syntheses of deuterium-labeled methyl-branched fatty acids

L12 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Syntheses of the stereoisomers of the sex pheromones of the southern corn rootworm and lesser tea tortrix

L12 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI α-Anions. VII. Direct oxidation of enolate anions to 2-hydroperoxy- and 2-hydroxycarboxylic acids and esters

L12 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of position-isomeric hydroxymethylpentadecanes

L12 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Dicarboxylic acids from undecylenic acid by carboxylation with acid catalysts

L12 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Effect of sodium tridecanedicarboxylates on the surface-active and washing properties of sodium tridecanemonocarboxylates

L12 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Free radical addition of carboxylic acids to α-olefins

L12 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Infrared spectrophotometric investigations of saturated linear and branched fatty acids

L12 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Soap hemolysis and fatty-acid structure

L12 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Oleophobic monolayers. I. Films adsorbed from solution in nonpolar liquids

=> d l12 1-15 ti

L12 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Diversity-Oriented Asymmetric Synthesis of Hapalosin: Construction of Three Small C9/C4/C3-Modified Hapalosin Analogue Libraries

L12 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Method for treating dementia or alzheimer's disease using a CD20 antibody

L12 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity

L12 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Nerve regeneration promoters containing fatty acid compounds

L12 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of branched carboxylic acid compound and use thereof

L12 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of (2R)-2-propyloctanoic acid

L12 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice

L12 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Development of new chiral auxiliary derived from (S)-(-)-phenylethylamine for a synthesis of enantiopure (R)-2-propyloctanoic acid

L12 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease

L12 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Fenton and photo-Fenton oxidation of textile effluents

L12 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of substituted lactams as inhibitors of aβ protein

production

L12 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of phenoxyalkanoic acids as drug delivery agents

L12 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Recording sheet for ink-jet printing

L12 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Branched-chain fatty acids, their derivatives, preparation, and use in the treatment of central nervous system disorders

L12 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Phosphonate, hydroxyphosphinyl, and phosphoramidate inhibitors of N-acetylated α-linked acidic dipeptidase (NAALADase) enzyme activity, preparation thereof, and therapeutic use

=> d l12 12 ti fbib abs

L12 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of phenoxyalkanoic acids as drug delivery agents
AN 2001:338472 CAPLUS
DN 134:353172
TI Preparation of phenoxyalkanoic acids as drug delivery agents
IN Leone-Bay, Andrea; Kraft, Kelly; Moye-Sherman, Destardi; Gschneidner, David; Boyd, Maria A. P.; Liu, Puchun; Tang, Pinwah; Liao, Jun; Smarth, John E.; Freeman, John J., Jr.
PA Emisphere Technologies, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2001032596	A1	20010510	WO 2000-US30662		20001106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
	CA 2388240	A1	20010510	CA 2000-2388240		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
	BR 2000015567	A	20020716	BR 2000-15567		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
	EP 1226104	A1	20020731	EP 2000-979142		20001106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906

				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
JP 2003513060	T	20030408		JP 2001-534752		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
NZ 530450	A	20040625		NZ 2000-530450		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
AU 783157	B2	20050929		AU 2001-16554		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	A	20001106
HU 200600033	A2	20060828		HU 2006-33		20001106
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
RU 2300516	C2	20070610		RU 2002-114698		20001106
				US 1999-163806P	P	19991105
				WO 2000-US30662	W	20001106
ZA 2002002365	A	20021025		ZA 2002-2365		20020325
				US 1999-163806P	P	19991105
MX 2002PA04451	A	20021023		MX 2002-PA4451		20020503
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
US 7129274	B1	20061031		US 2002-129467		20020503
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
AU 2005248960	A1	20060202		AU 2005-248960		20051229
				AU 2001-16554	A3	20001106
				WO 2000-US30662	W	20001106
AU 2005248981	A1	20060202		AU 2005-248981		20051229
				AU 2001-16554	A3	20001106
				WO 2000-US30662	W	20001106
US 2006264513	A1	20061123		US 2006-458331		20060718
				US 1999-163806P	P	19991105
				US 2000-231836P	P	20000906
				US 2000-237233P	P	20001002
				WO 2000-US30662	W	20001106
				US 2002-129467	A1	20020503

PATENT FAMILY INFORMATION:

FAN 2001:338308

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032130	A2	20010510	WO 2000-US41960	20001106
	WO 2001032130	A3	20020314		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 1999-163806P	P	19991105

			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
CA 2390025	A1	20010510	CA 2000-2390025		20001106
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
			WO 2000-US41960	W	20001106
AU 200126223	A	20010514	AU 2001-26223		20001106
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
			WO 2000-US41960	W	20001106
EP 1226109	A2	20020731	EP 2000-989761		20001106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
			WO 2000-US41960	W	20001106
JP 2004501057	T	20040115	JP 2001-534338		20001106
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
			WO 2000-US41960	W	20001106
NZ 530450	A	20040625	NZ 2000-530450		20001106
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
ZA 2002002365	A	20021025	ZA 2002-2365		20020325
			US 1999-163806P	P	19991105
MX 2002PA04092	A	20030212	MX 2002-PA4092		20020424
			US 1999-163806P	P	19991105
			US 2000-231836P	P	20000906
			US 2000-237233P	P	20001002
			WO 2000-US41960	W	20001106

OS MARPAT 134:353172

AB R1OZ1Z2CO2H [I; R1 = (un)substituted Ph; Z1 = (heteroatom-interrupted) alk(en)ylene or (hetero)arylene; Z2 = bond, (hydroxy)arylene, haloarylene] were prepared Thus, 2-(HO)C6H4OCH2Ph was etherified by Br(CH2)6CO2Et and the product deprotected to give 2-(HO)C6H4O(CH2)6CO2H. Data for drug delivery activity of I were given.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 14 ti fbib abs

L12 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN

TI Branched-chain fatty acids, their derivatives, preparation, and use in the treatment of central nervous system disorders

AN 1999:64764 CAPLUS

DN 130:119607

TI Branched-chain fatty acids, their derivatives, preparation, and use in the treatment of central nervous system disorders

IN Vinikova, Marina; Shapiro, Israel; Kozak, Alexander

PA D-Pharm Ltd., Israel

SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 9902485	A1	19990121	WO 1998-IL316	19980707
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				IL 1997-121268	A 19970709
	CA 2294276	A1	19990121	CA 1998-2294276	19980707
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
	AU 9881266	A	19990208	AU 1998-81266	19980707
	AU 740482	B2	20011108		
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
	EP 1009734	A1	20000621	EP 1998-931001	19980707
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
	HU 200003298	A2	20010228	HU 2000-3298	19980707
				IL 1997-121268	A 19970709
	JP 2001509500	T	20010724	JP 2000-502014	19980707
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
	ZA 9811775	A	19990629	ZA 1998-11775	19981222
				WO 1998-IL316	W 19980707
	US 6251946	B1	20010626	US 2000-462533	20000411
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
	US 2002042445	A1	20020411	US 2001-888958	20010625
	US 6518311	B2	20030211		
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
				US 2000-462533	A2 20000411
	IN 2001DE01158	A	20050311	IN 2001-DE1158	20011116
				IL 1997-121268	A 19970709
	US 2004235949	A1	20041125	US 2004-481975	20040428
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
				US 2000-462533	A2 20000411
				US 2001-888958	A2 20010625
				WO 2002-IL502	W 20020624

PATENT FAMILY INFORMATION:

FAN 2002:276525

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002042445	A1	20020411	US 2001-888958	20010625
	US 6518311	B2	20030211		
				IL 1997-121268	A 19970709
				WO 1998-IL316	W 19980707
				US 2000-462533	A2 20000411
	WO 9902485	A1	19990121	WO 1998-IL316	19980707
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

				IL 1997-121268	A	19970709
US 6251946	B1	20010626		US 2000-462533		20000411
				IL 1997-121268	A	19970709
				WO 1998-IL316	W	19980707
CA 2450946	A1	20030103		CA 2002-2450946		20020624
				US 2001-888958	A	20010625
				WO 2002-IL502	W	20020624
WO 2003000173	A2	20030103		WO 2002-IL502		20020624
WO 2003000173	A3	20040304				

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-888958	A	20010625
AU 2002314503	A1	20030108		AU 2002-314503		20020624
AU 2002314503	A2	20030108				
				US 2001-888958	A	20010625
				WO 2002-IL502	W	20020624
EP 1419129	A2	20040519		EP 2002-741140		20020624

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

				US 2001-888958	A	20010625
				WO 2002-IL502	W	20020624
JP 2005500305	T	20050106		JP 2003-506619		20020624
				US 2001-888958	A	20010625
				WO 2002-IL502	W	20020624
US 2004235949	A1	20041125		US 2004-481975		20040428
				IL 1997-121268	A	19970709
				WO 1998-IL316	W	19980707
				US 2000-462533	A2	20000411
				US 2001-888958	A2	20010625
				WO 2002-IL502	W	20020624

FAN 2004:1019793

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 2004235949	A1	20041125	US 2004-481975		20040428
				IL 1997-121268	A	19970709
				WO 1998-IL316	W	19980707
				US 2000-462533	A2	20000411
				US 2001-888958	A2	20010625
				WO 2002-IL502	W	20020624
	WO 9902485	A1	19990121	WO 1998-IL316		19980707

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

				IL 1997-121268	A	19970709
US 6251946	B1	20010626		US 2000-462533		20000411
				IL 1997-121268	A	19970709
				WO 1998-IL316	W	19980707
US 2002042445	A1	20020411		US 2001-888958		20010625
US 6518311	B2	20030211				
				IL 1997-121268	A	19970709

WO 1998-IL316 W 19980707
US 2000-462533 A2 20000411
WO 2003000173 A2 20030103 WO 2002-IL502 20020624
WO 2003000173 A3 20040304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-888958 A 20010625

OS MARPAT 130:119607

AB Compds. R1CH(A)R2 (R1 = (un)saturated C1-5 chain; R2 = (un)saturated C3-10 chain;
A = COOL, CONR'R''; L = lipid moiety selected from glycerol, C3-20 fatty acid monoglycerides, C3-20 fatty acid diglycerides, hydroxy -C2-6-alkyl esters of C3-20 fatty acids, hydroxy-C2-6-alkyl esters of lysophosphatidic acids, lyso plasmalogens, lysophospholipids, lysophosphatidic acid amides, glycerophosphoric acids, sphingolipids, lysophosphatidylethanolamines, N-mono and N,N-di-(C1-4)alkyl derivs. of the amines thereof; R', R'' = H, C1-5 alkyl), and pharmaceutically acceptable salts thereof, are provided. In addition, methods are provided for using these compns. for the treatment of CNS disorders.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 19 ti fbib abs

L12 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI α-Anions. VII. Direct oxidation of enolate anions to 2-hydroperoxy- and 2-hydroxycarboxylic acids and esters
AN 1975:592496 CAPLUS
DN 83:192496
TI α-Anions. VII. Direct oxidation of enolate anions to 2-hydroperoxy- and 2-hydroxycarboxylic acids and esters
AU Konen, D. A.; Silbert, L. S.; Pfeffer, P. E.
CS East. Reg. Res. Cent., U. S. Dep. Agric., Philadelphia, PA, USA
SO Journal of Organic Chemistry (1975), 40(22), 3253-8
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
AB 2-Hydroperoxy acids were obtained by direct low temperature (e.g., -75°) oxygenation of enolate dianions of straight- and branched-chain aliphatic carboxylic acids. Esters of 2-hydroperoxy acids were similarly obtained from ester enolate anions or by diazomethane reaction with 2-hydroperoxy acids. 2-Hydroxy acids were formed directly and nearly quantitatively by dianion oxygenation at room temperature Stabilities, decompositions, and products of decomposition of the hydroperoxy acids and their esters were described.

=> d l12 5 ti fbib abs

L12 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of branched carboxylic acid compound and use thereof
AN 2005:55187 CAPLUS
DN 142:134202
TI Preparation of branched carboxylic acid compound and use thereof

IN Imawaka, Haruo; Hasegawa, Tomoyuki; Sakuyama, Shigeru; Kawanaka, Yasufumi; Akiyama, Tsutomu; Hoshikawa, Masamitsu; Matsuda, Saiko

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005005366	A1	20050120	WO 2004-JP10366	20040714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2003-274988	A 20030715
EP 1650182	A1	20060426	EP 2004-747782	20040714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
			JP 2003-274988	A 20030715
			WO 2004-JP10366	W 20040714
US 2007167522	A1	20070719	US 2006-564720	20060117
			JP 2003-274988	A 20030715
			WO 2004-JP10366	W 20040714

OS MARPAT 142:134202

GI



I

AB A branched alkanoic acid represented by the general formula (I) (wherein R1 = optionally protected hydroxy or oxo; a wavy line indicates α configuration, β configuration, or a mixture of these in an arbitrary proportion; n = an integer of 1 to 3; m = an integer of 0 to 10, provided that two or more R1's are not bonded to the same carbon atom other than the terminal carbon atoms), a salt of the compound, or a prodrug of either is prepared The compound I is effective in, e.g., improving the function of astrocytes. It is useful as a preventive and/or therapeutic agent for brain infarction or nerve function disorders after brain infarction and for neurodegenerative diseases such as Parkinson's disease, Parkinson's syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease. Thus, a solution of 31 g (4S)-N-[(2R)-7-oxo-2-propyloctanoyl]-4-isopropyloxazolidin-2-one in 310 mL THF and 31 mL H2O was treated with 45.3 mL 30 weight% H2O2 at 6° and then dropwise with 100 mL 2 M aqueous LiOH at 5°, stirred at 24° for 3 h, treated dropwise with 300 mL 2 M NaNO2, stirred at 26° for 1 h to give, after workup and

silica gel chromatog., (2R)-7-oxo-2-propyloctanoic acid (II). II at 30 μmol/L in vitro significantly reduced cellular S100β protein in astrocytes from 2,177.0±147.74 to 1,489.0±37.84 (ng/mg). Pharmaceutical formulations, e.g. tablet containing II, were prepared

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.00	292.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.90

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:55:07 ON 05 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 08:02:58 ON 05 SEP 2007
FILE 'CAPLUS' ENTERED AT 08:02:58 ON 05 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.00	292.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.90

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.00	292.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.90

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:03:15 ON 05 SEP 2007